The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Other Long Term Assets: BDT18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBNSINA The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
45 GF Score
Price BDT316.70
GF Value BDT380.59
Valuation Modestly Undervalued
View Full Analysis

What is The IBN SINA Pharmaceutical Industry Other Long Term Assets?

The IBN SINA Pharmaceutical Industry DHA:IBNSINA +1.28% 45 Other Long Term Assets is BDT18 Mil as of Mar. 2026. GuruFocus rates DHA:IBNSINA with a GF Score™ of 45/100 and a GF Value™ of BDT380.59 (Modestly Undervalued).

The IBN SINA Pharmaceutical Industry's other long-term assets for the quarter that ended in Mar. 2026 was BDT18 Mil.

The IBN SINA Pharmaceutical Industry's quarterly other long-term assets declined from Sep. 2025 (BDT22 Mil) to Dec. 2025 (BDT9 Mil) but then increased from Dec. 2025 (BDT9 Mil) to Mar. 2026 (BDT18 Mil).

The IBN SINA Pharmaceutical Industry's annual other long-term assets increased from Jun. 2023 (BDT9 Mil) to Jun. 2024 (BDT9 Mil) and increased from Jun. 2024 (BDT9 Mil) to Jun. 2025 (BDT34 Mil).

The IBN SINA Pharmaceutical Industry Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for The IBN SINA Pharmaceutical Industry's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The IBN SINA Pharmaceutical Industry Other Long Term Assets Chart

The IBN SINA Pharmaceutical Industry Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 8.80 9.05 33.72

The IBN SINA Pharmaceutical Industry Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.91 33.72 22.42 8.91 17.57
DHA:IBNSINA
45GF Score
The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The IBN SINA Pharmaceutical Industry Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of BDT18 Mil mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a Other Long Term Assets of BDT18 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on The IBN SINA Pharmaceutical Industry and its competitors.
Is The IBN SINA Pharmaceutical Industry's Other Long Term Assets too high?
The IBN SINA Pharmaceutical Industry's current Other Long Term Assets is BDT18 Mil. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's Other Long Term Assets compare to IMNPQ?
The IBN SINA Pharmaceutical Industry's Other Long Term Assets of BDT18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. The IBN SINA Pharmaceutical Industry's current Other Long Term Assets is BDT18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
Based on GuruFocus' analysis, The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT380.59, compared to a current price of BDT316.70 — trading 16.8% below its estimated fair value. The current Other Long Term Assets is BDT18 Mil. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current Other Long Term Assets is BDT18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Overvalued in 2026?

Based on GuruFocus' analysis, The IBN SINA Pharmaceutical Industry stock appears to be undervalued. The current stock price of BDT316.70 is trading 16.8% below its estimated GF Value™ of BDT380.59. GuruFocus considers The IBN SINA Pharmaceutical Industry to be Modestly Undervalued.

Key valuation signals for DHA:IBNSINA:

  • Other Long Term Assets: BDT18 Mil
  • GF Value™: BDT380.59 vs. price of BDT316.70 (16.8% below fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the DHA:IBNSINA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

The IBN SINA Pharmaceutical Industry Business Description

Address Mirpur Road, Tanin Center, 3 Asad Gate, Mohammadpur, Dhaka, BGD, 1207
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
45GF Score

Get the complete analysis for DHA:IBNSINA

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT316.70
Price
BDT380.59
GF Value